ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0925

IL-4 Acts Through Aryl Hydrocarbon Receptor to Antagonize TLR7-induced Double Negative 2 B Cells in Lupus

Changming Lu, Hui-chen Hsu, Min Gao, Jose Rubio, Winn Chatham and John Mountz, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2023

Keywords: B-Lymphocyte, cytokines, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0899–0933) SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet+ double negative 2 (DN2) B cells. Here we investigate the potential DN2 B-cell suppressive effects of IL-4 through the IL-4-induced 1 (IL-4i1)-aryl-hydrocarbon receptor (AhR) pathway.

Methods: The mechanism of IL-4 in suppressing the development of DN2 B cells in vivo was studied using R848-treated BXD2 mice. The B-cell developmental trajectory was determined using single-cell RNA-sequencing (scRNA-seq) analysis. Adult patients whomet theACR 1997 revised criteria for SLE were recruited. The in vitro effects of IL-4 and two potent AhR agonistic ligands, Kynurenine (Kyn) and 6-formylindolo[3,2-b]carbazole (FICZ) in suppressing the development of DN2 B cell were determined using IFNβ plus TLR7 stimulated B cells. B-cell subsets and transcription factors (TFs) expression was measured by surface and intra-nuclear FACS analysis. AhR pathway and target genes were analyzed using qPCR. Autoantibodies were measured by ELISA.

Results: Administration of IL-4 significantly inhibited the development of anti-Smith, anti-DNA, and anti-histone autoantibodies induced by the TLR7 agonist R848 in BXD2 mice. This was associated with a decreased percentage of CD11c+T-bet+ IgD− B cells. Feature-barcoding single-cell RNA-sequencing analysis showed that IL-4 modulated B-cell development at the transitional stage 2 (T2) and skewed naïve B cells to develop into the CD23+CD21− follicular B cells. IL-4 induced the gene encoding Ii4i1, an enzyme that metabolizes aromatic amino acids, and this was associated with the upregulation of AhR and downstream genes Cyp1a1 and Ido1. In the absence of IL-4, both Kyn and FICZ significantly suppressed TLR7 plus IFNβ-induced T-bet+ B-cell development in vitro in BXD2 mice. Analysis of AhR expression in healthy control (HC) and SLE subjects show a significantly lower expression of AhR in both the IgD−CD27− DN and IgD+CD27− naïve B-cell populations of SLE compared to HC. qPCR analysis further indicates a significantly lower expression of CYP1A1 and IL4I1 in SLE B cells compared to HC B cells. B cell culture with either IL-4 or Kyn significantly reduced the development of DN2 B cells stimulated by IFNβ plus TLR7. Kyn also significantly induced the expression of CYP1A1 and promoted the expression of PD-1 in IFNβ plus TLR7-stimulated B cells.

Conclusion: Our results suggest that IL-4R acts through the IL4i1-AhR pathway to induce a B-cell regulatory response to TLR7 and type I IFN. Identifying small molecular metabolites that act directly in B cells to induce homeostasis may lead to the development of orally active druggable targets that are efficacious in treating SLE.


Disclosures: C. Lu: None; H. Hsu: None; M. Gao: None; J. Rubio: None; W. Chatham: None; J. Mountz: None.

To cite this abstract in AMA style:

Lu C, Hsu H, Gao M, Rubio J, Chatham W, Mountz J. IL-4 Acts Through Aryl Hydrocarbon Receptor to Antagonize TLR7-induced Double Negative 2 B Cells in Lupus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/il-4-acts-through-aryl-hydrocarbon-receptor-to-antagonize-tlr7-induced-double-negative-2-b-cells-in-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-4-acts-through-aryl-hydrocarbon-receptor-to-antagonize-tlr7-induced-double-negative-2-b-cells-in-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology